Teva’s Cinqair To Join Nucala For Severe Asthma After FDA Approval
FDA approved the interleukin-5 antagonist reslizumab March 23 for the treatment of severe asthma in patients 18 and older who have an eosinophilic phenotype.
FDA approved the interleukin-5 antagonist reslizumab March 23 for the treatment of severe asthma in patients 18 and older who have an eosinophilic phenotype.